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Background: Macrophage migration inhibitory factor (MIF) is a cytokine that shares many activities with other pro-
inflammatory cytokines in primary glomerulonephritis (GN). This study assesses the influence of immunosuppressive
treatment on serum and urine MIF in patients with proliferative (PGN) and non-proliferative (NPGN) glomerulonephritis,
and evaluates the potential of MIF in predicting outcomes.
Methods: Eighty-four patients (45 males and 39 females) with primary GN were included. Urinary excretion of
MIF (ng/mg of urinary creatinine) was measured both pre- and post-treatment with combined steroids and
cyclophosphamide. After a 12-month follow-up, the patients were retrospectively divided into four subgroups:
responders of proliferative GN (R-PGN), non-responders of proliferative GN (NR-PGN), responders of non-
proliferative GN (R-NPGN) and non-responders of non-proliferative GN (NR-NPGN).
Results: The median pre-treatment urinary MIF values were higher in PGN than in NPGN (3.6 versus 2.2; ANOVA
P = 0.039). The highest pre-treatment urinary excretion of MIF was observed in NR-PGN (median 6.1), which was
significantly higher than other subgroups (ANOVA P < 0.05). The treatment significantly reduced MIF urinary
excretion only in R-PGN (P < 0.01). In NR-PGN, pre- (5.9 ± 2.9 pg/mgCr) and post-treatment mean MIF excretion
(4.9 ± 2.3 pg/mgCr) exceeded the calculated cut off value (3.3 pg/mgCr).
Conclusion: MIF urinary excretion appears to be a prognostic marker of therapy outcomes only in proliferative
glomerulonephritis, in which lower urinary MIF may be linked with good prognosis, whereas a higher MIF
urinary excretion value was a marker of unfavorable therapy outcomes. In Non-Responders, urinary MIF
measurements may help to reconsider the choice of the immunosuppressive regimen at early stages of the
treatment and act as an impulse to search for new therapeutic strategies.
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Background
Macrophage migration inhibitory factor (MIF) is a cytokine
that shares many activities with other pro-inflammatory
cytokines, and activates macrophages by promoting the
synthesis of such cytokines as tumor necrosis factor-α,
interleukin (IL)-1β, and IL-8 [1–3]. Together with these
cytokines, it plays a pivotal role in mediating renal injury in
experimental nephritis, including glomerulonephritis. The
upregulation of MIF in the glomerular mesangial cells and
tubular epithelial cells has been found to correlate with
progressive renal injury [4–6].
Furthermore, H.Y. Lan et al. report that MIF expres-
sion examined by in situ hybridization of specimens ob-
tained from kidney biopsies of various types of primary
glomerulonephritis (GN) is markedly upregulated in
proliferative forms of human GN [4]. In an experimental
GN model, anti-MIF treatment has been found to
ameliorate kidney injury, limiting the activation of effector
cell, particularly macrophages, and influencing the relation-
ship between infiltrating and local cells [7, 8].
Primary glomerulonephritis, with or without the infil-
tration of inflammatory cells, is regarded as an immune-
mediated disease affecting both the glomeruli and inter-
stitium [9]. Proliferative (PGN) and non-proliferative
(NPGN) types of GN were historically differentiated by
the presence of leukocyte infiltration, cell proliferation
and an imbalance of glomerular extracellular matrix
turnover, i.e., the predominance of its production or deg-
radation, as well as their involvement in the injury of
kidney structures [10, 11]. Types of proliferative primary
glomerulonephritis include mesangial proliferative GN
(MesGN), membrano-proliferative GN (MPGN) and
immunoglobulin A nephropathy (IgAN), while types of
non-proliferative GN include minimal change disease
(MCD), focal glomerulosclerosis (FSGS), and membran-
ous nephropathy (MN) [10, 11].
Immunosuppressive therapy (IS) based on the use of cor-
ticosteroids and non-specific cytotoxic agents commonly
administered in GN remains the elementary therapeutic
weapon for immune modification in primary glomerulo-
nephritis. However, this treatment, which modifies immune
glomerular injury, remains nonspecific, with a high inci-
dence of side effects and only moderate efficacy [8, 12–17].
Due to the unpredictable course of GN and response
to therapy, treatment individualization and optimization
is often impossible. Hence, the search continues for
more reliable predictors which might allow individually
tailored and adequate immunosuppressive treatment
schemes to be implemented. This study was therefore
conducted to determine whether in severe courses of GN,
MIF may be regarded as a complementing factor when de-
ciding to introduce aggressive treatment in sensitive cases,
or whether it can be disqualified as a factor preventing IS
complications. The objectives of the study were, therefore:
– to compare patients with primary GN and healthy
participants with regard to the serum concentration
and urinary excretion of MIF,
– to assess the influence of immunosuppressive
treatment on the serum and urine MIF levels in
patients with proliferative and non-proliferative
primary GN and,
– to evaluate the potential of using MIF serum
concentration and urine excretion measurements to




The study was conducted in 84 patients (45 male and 39
female) with primary glomerulonephritis: mean age
41.44 ± 13.25 years. The control group consisted of 18
age-matched healthy subjects. The profiles of the study
group, including glomerulonephritis-type divisions, and
the control group are shown in Table 1. Only patients
with a severe course of GN were included in this study,
i.e., those who demonstrated deterioration of kidney
function, reflected in an increase of serum creatinine
concentration by more than 50 % of baseline values or
nephrotic range proteinuria, despite steroid treatment.
The diagnosis was established based on clinical symp-
toms, laboratory tests, kidney biopsy and accessory in-
vestigations. All of the biopsy specimens were evaluated
by light, electron and immunofluorescence microscopy
in the Department of Kidney Pathology, Medical Univer-
sity of Lodz. In addition, the percentage of interstitial
volume was calculated using a computerized morpho-
metric analysis of interstitium quantity. According to a
scoring system proposed by G. Fuiano et al., the degree
of glomerulosclerosis (GSC), based on the number of
involved glomeruli, and the intraglomerular extent of
sclerosis were semi-quantitatively estimated [18–21].
The degree of GSC was graded on a four-point scale:
normal (0), mild (1), moderate (2) and severe (3). The
type of primary glomerulonephritis was identified by
microscopic evaluation, and mesangio-proliferative GN
was diagnosed after the exclusion of other types of pro-
liferative glomerulonephritis. Also, the urinary excretion
of proteins, expressed in milligrams per milligram of
creatinine in urine (mg/mg Cr) was measured, together
with total serum protein content.
All participants were treated with antihypertensive
drugs (angiotensin-converting enzyme inhibitor - rami-
pril or angiotensin receptor blocker – losartan and cal-
cium channel blocker - amlodipine) to establish and
maintain blood pressure values in an accordance with
recommendations [22, 23]. In addition, statins were in-
troduced to stabilize the lipid profile (atorvastatin at a
mean dose of 20 mg/day) with the aim of reducing low
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density lipoprotein (LDL) serum concentration to below
100 mg/dl [24]. These variables were assessed at baseline
and then serially throughout the course of treatment to
monitor the status of the patients. Finally, all tests were
repeated after 1 year (±3 months) of immunosuppressive
treatment. The structure of the subgroups, divided
according to type of primary glomerulonephritis, is
presented in Table 1.
IS protocol
All subjects received an identical immunosuppressive
protocol which consisted of initial pulse therapy with
methylprednisolone, i.e., a calculated aggregate dose of
1000 mg per 20 kg body weight administered every
other day, followed by oral prednisone (25–30 mg/day)
and cyclophosphamide in 6 monthly pulses given at
0.6 g/b.m2. The cumulative dose of cyclophosphamide
did not exceed 6 g. Before the initiation of treatment,
the potential foci of infection were diagnosed and elimi-
nated as routine in all participants. A treatment scheme
based on pulses of steroids and cyclophosphamide
(CPH) was restricted to cases of progressive GN with a
severe disease course (decreasing eGFR) and was chosen
as a rescue protocol. The introduction of cyclophospha-
mide as primary treatment is controversial in different
types of GN, despite many authors describing it as offer-
ing greater benefits than other immunosuppressive
agents. CPH pulse treatment combined with steroids is
regarded as well tolerated and effective, especially in
steroid-dependent or corticosteroid-resistant severe
nephrotic syndrome, or in GN with progressive worsen-
ing of eGFR and diffuse microscopic lesions, irrespect-
ive of primary glomerulonephritis type [25–35].
MIF analysis
The blood and urine of healthy participants, as well as pre-
and post-treatment blood and urine samples from patients,
were prospectively collected to EDTA (ethylenediaminetet-
raacetic acid) tubes, centrifuged and stored at −70 °C until
analysis. When completed, the serum concentrations
and urinary excretion of MIF were measured by
enzyme-linked immunosorbent assay (ELISA) using
commercial immunoassays according to the manufac-
turer’s instructions (Biosource® Europe S.A., Nivelles,
Belgium). All tests were performed in the Department
of Medical Laboratory Diagnostics, Barlicki Memorial
Teaching Hospital No.1, Medical University of Lodz: a
certified RIQAS local laboratory (Randox International
Quality Assessment Scheme and SNCS IQAS e-CHECK -
Sysmex International Quality Assurance System).
To evaluate the potential value of MIF in predicting GN
outcomes after 1 year of treatment, patients with PGN
and NPGN were divided retrospectively into subgroups
according to their response to the therapy: R – Re-
sponders (proteinuria < 0.5 g/day, e.g., < 6 mg/mg urine Cr
and improved or stable kidney function – serum creatin-
ine change within a range of 15 %), NR – Non-
Responders (proteinuria > 0.5 g/day, e.g., > 6 mg/mg urine
Cr and/or deterioration of kidney function – over 15 % in-
crease of serum creatinine concentration). These are in ac-
cord with previous study methodology [36, 37]. When
completed, the division allowed MIF to be evaluated retro-
spectively at baseline in R and NR.
To verify the value of MIF measurements in predicting
GN-favorable outcomes, as well as to confirm the value
of abnormal MIF urine excretion in indicating worse
pre-treatment prognosis, the cut off value was calculated
using an ROC curve.
Statistical analysis
Comparisons within and between groups were made
with the non-parametrical Kruskal-Wallis ANOVA for
multivariable analysis, the Fisher’s exact probability test
was used for sex comparison and the Wilcoxon’s rank
Table 1 The structures of the study group (including subdivisions) according to primary glomerulonephritis type, and the control group
Gender Age (years) ± SD Subgroup
Male Female Mean Responders Non-responders
Non-Proliferative GN
MCD 3 7 36.0 ± 16.47 8 2
FSGS 9 3 40.83 ± 13.17 7 5
MN 5 6 45.81 ± 13.44 7 4
Proliferative GN
MesGN 8 12 39.45 ± 15.34 13 7
IgAN 10 10 39.80 ± 14.20 12 8
MPGN 10 1 42.27 ± 11.88 6 5
pooled 45 39 41.44 ± 13.25 53 31
Healthy 10 8 36.11 ± 13.29 - -
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sum test to evaluate changes of clinical parameters dur-
ing the treatment. Relations between variables were ana-
lyzed by Spearman rank (R) correlation coefficients. A
logistic regression was performed to analyze potential con-
founders in the cohort. Differences were considered signifi-
cant for p < 0.05. The results were expressed, as mean ±
standard deviation or median (range) as appropriate.
Ethics statement
The study protocol was approved by the Medical University
of Łódź Bioethics Committee, Resolution No. RNN/9/04/
KE. According to the principles of good clinical practice
(GCP), informed consent was obtained from all patients
prior to their inclusion in the study.
Results
Clinical data
The clinical data, grouped according to subgroup structure,
type of primary glomerulonephritis and patient response to
IS, is presented in Table 2. No differences in distribution
were noticed between the R and NR subgroups, nor
were any differences found with regard to coexisting
comorbidities, including diabetes, obesity or severe
infections, which might affect the final evaluation in
both subgroups. The gender structure in the subgroups
was homogenous, and the subgroups were matched ac-
cording to sex and age.
As shown in Table 2, no statistically significant differ-
ences in biopsy findings, such as percentage of interstitium
Table 2 Biopsy findings and biochemical parameters in proliferative and non-proliferative glomerulonephritis patients after division
into Responders and Non-Responders subgroups (mean ± SD)
Proliferative GN Non-proliferative GN
Responders (R) Non-Responders (NR) Responders (R) Non-Responders (NR)
Patients (n) 31 20 22 11
Uncontrolled hypertension (n) 3 2 2 2
ACE-I or ARB treatment(n) 29 18 21 11
Interstitium volume (%) ± SD 30.3 ± 2.27b,c 31.1 ± 3.11d,e 14.2 ± 5.47b,d 15.03 ± 7.35c,e
Median 22.3 21.5 16.7 18.3
Glomerulosclerosis (grade) ± SD 1.65 ± 0.81 1.68 ± 0.74 2.66 ± 0.51 2.59 ± 0.61
Median 1.88 1.99 2.24 2.15
Mesangial cellularity 1.45 ± 0.28 1.39 ± 0.19 0.96 ± 0.11 0.87 ± 0.19
Median 1.22 1.19 0.99 0.91
Serum creatinine before treatment (mg %) ± SD 1.88 ± 1.01 1.86 ± 1.1 1.45 ± 1.19 1.66 ± 1.4
Median 1.75 1.73 1.59 1.61
Serum creatinine after treatment (mg %) ± SD 1.40 ± 1.42a,c 2.17 ± 1.61 1.23 ± 1.14d,f 2.39 ± 1.74
Median 1.39 1.93 1.24 2.27
LDL before treatment (mg/dl) ± SD 126 ± 41.1a,b,c 139 ± 39.7 145.7 ± 39.1 146.8 ± 41.7
Median 122.2 137.5 141.7 142.6
LDL after treatment (mg/dl) ± SD 87.9 ± 10.4 88.8 ± 11.1 88.1 ± 9.9 89.5 ± 11.6
Median 86.6 87.9 88.0 88.4
Total serum proteins before treatment (g/dl) ± SD 6.02 ± 0.55 6.11 ± 0.58 5.51 ± 1.82 5.48 ± 1.78
Median 5.88 5.91 5.55 5.69
Total serum proteins after treatment (g/dl) ± SD 6.42 ± 0.62a,c 5.64 ± 0.81a,d 6.65 ± 0.6d,f 5.24 ± 0.89c,f
Median 6.56 5.54 6.74 5.31
Proteins urine excretion before treatment (mg/mg Cr) ± SD 11.4 ± 2.44b,c 12.1 ± 6.08d,e 61.25 ± 9.4b,d 58.90 ± 88.18c,e
Median 10.5 11.0 58.5 51.3
Proteins urine excretion after treatment (mg/mg Cr) ± SD 1.58 ± 3.1a,b,c 2.96 ± 9.14a,e 5.55 ± 2.25b,f 19.9 ± 14.3b,c,e,f
Median 1.31 2.66 3.88 16.74
Differences were considered significant for P < 0.05 (Kruskal-Wallis ANOVA)
aProliferative GN R versus NR
bProliferative GN R versus non-proliferative GN R
cProliferative GN R versus non-proliferative GN NR
dProliferative GN NR versus non-proliferative GN R
eProliferative GN NR versus non-proliferative GN NR
fNon-proliferative GN R versus NR
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volume and glomerulosclerosis grade, or biochemical pa-
rameters, such as total serum protein content and serum
creatinine concentration, were observed between R and NR
subgroups in either type of GN for all comparisons before
treatment. In proliferative GN, the only parameter which
differed between both subgroups was the presence of a sig-
nificantly reduced pre-treatment LDL serum concentration
in the R subgroup. In both subgroups of non-proliferative
GN, pre-treatment urine excretion of protein was signifi-
cantly greater than in proliferative GN. Before treatment,
significant positive correlations were found between
serum creatinine concentration and interstitium vol-
ume (ρ = 0.263, P = 0.029), and glomerulosclerosis
grade (ρ = 0.294, P = 0.036) in proliferative glomerulo-
nephritis. Also, in non-proliferative primary glomer-
ulonephritis, a positive correlation was also noted
between serum creatinine and interstitium volume
(ρ = 0.28, P = 0.043), and glomerulosclerosis grade
(ρ = 0.22, P = 0.038).
When analyzing the R and NR subgroups for both prolif-
erative and non-proliferative primary glomerulonephritis
during the post-treatment period, total serum protein level
was significantly higher in the R subgroup, while, as ex-
pected, serum creatinine concentration and protein urine
excretion were significantly lower in the R subgroup, and
followed from assumed subdivision to Responders and
Non-Responders However, no difference in post-treatment
protein urine excretion was observed between the NR pro-
liferative and R non-proliferative glomerulonephritis. The
introduction of statins resulted in post-treatment LDL re-
duction, and serum LDL concentrations did not differ sig-
nificantly between the proliferative and non-proliferative
GN groups for both the R and NR subgroups. The results
are presented in Table 2.
Serum MIF
Serum MIF levels before treatment did not differ signifi-
cantly between proliferative and non-proliferative pri-
mary GN patients. The MIF serum concentration in
patients with both types of GN were significantly higher
than in healthy subjects (P = 0.021 and P = 0.036, re-
spectively). The results are presented in Table 3. No dif-
ference was seen between the R and NR subgroups with
regard to pre-treatment MIF serum concentration, irre-
spective of whether proliferative or non-proliferative pri-
mary glomerulonephritis was analyzed (Table 4).
Although, the post-treatment mean serum MIF values
were slightly lower in proliferative GN, both for the R
versus NR and in non-proliferative GN for the R versus
NR subgroups (i.e., 1.1 ± 0.7 vs. 2.4 ± 1.1 and 1.6 ± 0.8
vs.1.8 ± 0.9 ng/ml, respectively), the observed reductions
were not statistically significant. With respect to pre and
post-treatment MIF, no correlations between serum
concentration and other cofounders were found, irre-
spective of the type of primary glomerulonephritis.
Urinary MIF
Greatly increased MIF urinary excretion was observed in
patients with proliferative and non-proliferative primary
glomerulonephritis compared to controls (P = 0.006 and
P = 0.009 – Table 3). The urinary excretion of MIF before
treatment positively correlated with interstitium volume,
glomerulosclerosis grade and serum creatinine concen-
tration: ρ = 0.29, P = 0.036; ρ = 0.24, P = 0.038; ρ = 0.31,
P = 0.039, respectively.
Urinary MIF was higher in PGN than in NPGN
(P = 0.039). The treatment reduced urinary MIF in both
primary glomerulonephritis types, irrespective of the
response to treatment (R and NR subgroups), but MIF
urinary excretion was only found to be significantly
lower in Responders with PGN (P = 0.007) – Fig. 1. All
results are presented in Table 3. The pre-treatment
MIF urinary excretion value in PGN positively corre-
lated with interstitium volume, glomerulosclerosis grade
and serum creatinine concentration: ρ = 0.28, P = 0.03;
ρ = 0.3, P = 0.037; ρ = 0.34, P = 0.026; respectively.
In non-proliferative GN, MIF urinary excretion did
not differ between the R and NR subgroups. In contrast,
in proliferative glomerulonephritis, the urinary excretion
of MIF was significantly higher in the NR than the R
subgroup (Table 4). It is noteworthy that MIF excretion
in the R subgroup was significantly greater than that ob-
served in the R and NR subgroups in non-proliferative
GN. Interestingly, urinary MIF levels in the Responders
subgroup of proliferative GN were found to be similar
to those of both the R or NR subgroups in non-
proliferative GN (Table 4).
Table 3 Pre-treatment serum concentration and urinary






Proliferative GN Mean ± SD 2.2 ± 1.0 4.2 ± 2.1
Median (range) 1.9 (1.1–3.4) 3.6a,b (2.0–8.1)
Non-proliferative GN Mean ± SD 1.8 ± 0.3 3.0 ± 1.9
Median (range) 1.3 (1.0–2.4) 2.2c (1.7–4.3)
Pooled Mean ± SD 1.7 ± 0.8 3.7 ± 1.9
Median (range) 1.7 (1.0–3.3) 3.2 (1.7–8.1)
Healthy Mean ± SD 0.2 ± 0.01 0.5 ± 0.02
Median (range) 0.2 (0.18–0.21) 0.5 (0.4–0.5)
Differences were considered significant for P < 0.05 (Kruskal-Wallis ANOVA)
aProliferative GN versus Non-proliferative GN
bProliferative GN versus Healthy patients
cNon- proliferative GN before versus Healthy
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The calculated ROC curve indicated the cut-off value
for urinary MIF excretion as 3.3 pg/mg of urinary cre-
atinine, and the AUC was 0.87 (95 % CI 0.8–0.91). Only
the urinary excretion of MIF in Non-Responders in pro-
liferative primary GN was higher than the calculated
pre- (P = 0.009) and post-treatment (P = 0.013) cut-off
values. Furthermore, in no other subgroup was this limit
exceeded, neither before nor after IS treatment (Fig. 1).
The evaluation of pre-treatment urinary MIF values in
Non-Responders (proliferative GN) revealed a correl-
ation with post-treatment serum creatinine (ρ = 0.42,
P = 0.006) and proteinuria values (ρ = 0.44, P = 0.005).
The logistic regression analysis of the pre-treatment var-
iables indicated that only the urinary MIF was the exclu-
sive predictive marker of the treatment outcomes in the
whole cohort Table 5.
Discussion
Macrophage migration inhibitory factor (MIF) is a
potent pro-inflammatory cytokine which has been found
to have an important chemokine-like function (CLF)
which plays an essential role in monocyte recruitment
and arrest; It has also been recently redefined as a
pleiotropic inflammatory cytokine which has crucial roles
in both physiological immunity and inflammatory diseases
[1, 38–41]. Renal MIF expression was identified in normal
kidneys and it is upregulated in patients with glomerulo-
nephritis and renal allograft rejection. This upregulation of
MIF in GN is typically associated with leukocyte infiltration,
histopathological damage and kidney dysfunction in pa-
tients with inflammatory kidney disease [1, 4, 40, 41]. Most
authors assume increased urinary MIF excretion to be sig-
nificantly correlated with local – renal MIF upregulation ir-
respective of its serum level, which suggests that MIF may
be a suitable candidate as a marker for renal injury in
humans [41, 42]. K. Matsumoto et al. report MIF urinary
excretion to be significantly correlated with the grades of
mesangial matrix increase and interstitial fibrosis, as well as
with the number of both intraglomerular and interstitial
macrophages among patients with focal glomerular scler-
osis [43]. The authors also exclude any possible correlation
between the levels of urinary MIF and the severity of pro-
teinuria, which suggests that the detectability of MIF in
urine reflects a specific involvement in the disease process
of GN [43]. Furthermore, anti-MIF intervention in experi-
mental glomerulonephritis has revealed a generalized
Table 4 Pre-treatment serum concentration and urinary excretion of MIF in patients with proliferative and non-proliferative
glomerulonephritis (GN) after division into Responders (R) and Non-Responders (NR) subgroups
Serum MIF (ng/ml) Urinary MIF (ng/mg Cr)
Mean ± SD Median (range) Mean ± SD Median (range)
Proliferative GN R 1.3 ± 0.8 1.4 (1.1–1.5) 2.1 ± 1.3 2.4 (2.0–3.7)
NR 3.3 ± 1.2 3.0 (2.0–3.4) 5.9 ± 2.9 6.1a,b,c (2.9–8.1)
Non-proliferative GN R 1.7 ± 0.2 1.8 (1.0–2.0) 2.9 ± 1.8 2.2 (1.7–4.1)
NR 2.0 ± 0.4 1.9 (1.2–2.4) 3.1 ± 2.1 2.3 (1.9–4.3)
Differences were considered significant for P < 0.05 (Kruskal-Wallis ANOVA)
aProliferative GN NR versus proliferative GN R
bProliferative GN NR versus non-proliferative GN R
cProliferative GN NR versus non-proliferative GN NR
Fig. 1 Pre-treatment and post-treatment mean urinary excretion of MIF in proliferative and non-proliferative glomerulonephritis (GN) divided into
Responder (R) and Non-Responder (NR) subgroups
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downregulation of numerous pro-inflammatory cytokines,
chemokines and MIF-dependent signaling intermediates
[7, 8]. These conclusions are in agreement with observa-
tions concerning the protective effect of genetic MIF
deficiency on renal injury reported in MRL/MpJ-Faslpr
mice backcrossed onto a mif−/− background [40].
In the present study, only participants with severe pro-
teinuria and/or an increase of serum creatinine were se-
lected. Unsuccessful initial treatment with steroid therapy
(i.v. pulses) necessitated the need for combined treatment
with cyclophosphamide. Although this immunosuppres-
sive protocol exceeds the scope of standard therapy, many
authors confirm its efficacy in various types of primary
glomerulonephritis [25–35]. However, the patients to
be treated by this therapeutic strategy must be carefully
selected i.e., those who are known to have a severe
course of GN. In this study, one third of non-
proliferative glomerulonephritis and nearly 40 % of
patients with proliferative GN demonstrated no im-
provement in proteinuria and/or kidney function after
therapy and continued to 1 year follow-up, despite
combined treatment. This appears to confirm that the
clinical course of GN still remains unpredictable in a
significant number of patients, and that it is hard to
form a uniform therapeutic strategy. Furthermore, in
some cases, treatment options based on routine clinical
and biochemical assessments can be introduced, but
often in vain [44, 45]. As the initial introduction of less
radical immunosuppressive schemes may be insufficient,
more aggressive therapeutic strategies in those particularly
complicated cases merit further investigation [12–16].
In the present study, no differences were noted be-
tween pre- and post-treatment MIF serum concentra-
tions, irrespective of the type of glomerulonephritis.
Highly elevated serum MIF values seem to be associated
with a significant deterioration of kidney function in the
majority of participants, although the values were even
lower than those of MIF urinary excretion.
Urinary MIF excretion has been occasionally evaluated
[3, 43]. In this study, urinary MIF was found to be lower
after treatment in both the proliferative and non-
proliferative GN groups. R. Bucala reports that the low
expression of MIF alleles may protect the end-organ from
ensuing inflammatory damage, and the immunosuppressive
action of glucocorticoids may be most effectively applied in
those individuals who, on the basis of their genotype, mani-
fest an MIF-dependent form of autoimmunity [17].
However, significant reductions were demonstrated
only in PGN participants who responded to treatment.
On the contrary, K. Matsumoto et al. report that MIF
urinary excretion in patients with focal glomerular
sclerosis was significantly depressed immediately follow-
ing administration of isolated steroid therapy [43]. This
trend was also observed for Responders with PGN in
the present study, but only after the combined therapy
was administered. Hence, although the decrease in MIF
urinary excretion after the introduction of immunosup-
pressive therapy seems to be a good prognosis of favor-
able treatment outcome, it is not the case in all patients
with GN, but only in participants with proliferative
glomerulonephritis and in whom this reduction was sta-
tistically significant. Therefore, the significant reduc-
tion in urinary MIF excretion may reduce the synthesis
of a pathway of pro-inflammatory cytokines and de-
creases macrophages activity in both the glomeruli and
interstitium [7, 8].
It is noteworthy that MIF was the only parameter that
was found to vary between the Responders and Non-
Responders subgroups in the proliferative GN group. In
Non-Responders, the MIF urinary excretion values were
even higher than those seen in patients described by K.
Matsumoto et al., or after stimulation with pIgA pre-
pared from IgAN patients [3, 43]. Although all post-
treatment urinary MIF values were lower than those
seen in pre-treatment in both the R and NR subgroups,
the lowest value was still noted in responders with pro-
liferative GN. The present study suggests that lower
MIF urinary excretion may be associated with a good
prognosis, and increased excretion with the risk of GN
progression, which is in accord with other studies, al-
though it was also observed for non-proliferative GN
[3–6, 43]. However, MIF plays a crucial role in GN,
particularly proliferative types of GN, may be due to its
pro-inflammatory activity. Also, in proliferative GN,
the correlations between pre-treatment urinary MIF
and post-treatment creatinine and proteinuria shown
in the present study highlight the potential value of
MIF measurements as a marker of poor prognosis.
Among the patients with GN, urinary MIF significantly cor-
relates with the grade of mesangial matrix and interstitial
fibrosis as well as with both the intraglomerular and inter-
stitial macrophage infiltration rate [43]. However, these
Table 5 Multiple logistic regression analysis of the pre-
treatment variables which may influence the response to
the immunosuppressive treatment (the whole cohort of
Responders)
Estimation Odds ratio 95 % CL P-value
Interstitium volume −0.02 0.97 0.91–1.02 NS
Glomerulosclerosis (grade) −0.23 0.78 0.06–9.6 NS
Serum creatinine 0.63 1.8 0.85–4.1 NS
LDL 0.3 0.9 0.7–1.31 NS
Proteins urine excretion −0.03 0.96 0.92–1.0 NS
ACE-I, ARB treatment 0.12 1.12 0.22–5.62 NS
Serum MIF 0.04 1.3 0.99–1.6 NS
Urinary MIF −0.41 0.21 0.11–0.64 0.022
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may explain the correlations between urinary MIF and the
magnitude of proteinuria [44] and degree of renal dysfunc-
tion [41]: All those assessments were obtained before the
treatment was instituted. A review of extant literature
indicates, that the correlations between MIF and post-
treatment parameters have not been investigated at the
time of writing.
To verify the potency of MIF measurements in pre-
dicting GN, the cut off value of MIF urinary excretion
was calculated using an ROC curve. The results indi-
cated that MIF urinary excretion was higher only in
Non-Responders of proliferative primary GN, both pre-
and post-treatment, which is important in the light of
the present study. However, although proteinuria is
regarded as an independent risk factor and a predictor
of renal function deterioration in some types of primary
glomerulonephritis, it is not accurate at baseline in some
cases [39, 45]. In these cases, creatinine clearance,
hypertension and severity of biopsy pathological lesions
are key indicators [38, 46]. Surprisingly, in this study,
those risk factors traditionally regarded as contributory
for treatment outcome were found to be unreliable.
The decision to introduce immunosuppressive therapy
is strictly based on patient general status, clinical and
biochemical parameters. Additionally, the clinicians
individualize the treatment to achieve high effectiveness
and avoid therapeutic disadvantages based on their ex-
perience and existing guidelines The present findings
suggest that pre-treatment examinations of urinary MIF
may become an additional factor in the optimization of
treatment. Additionally MIF seems to be not only a po-
tent predictive marker but also may add impetus to the
search for new therapeutic strategies like anti-MIF
treatment which has been found to ameliorate kidney
injury in an experimental GN models [7, 8].
Nevertheless, further studies evaluating the value of
MIF urinary excretion measurements in GN, especially
the proliferative type, are needed.
Study limitations
As only a selected group of patients with a severe
course of GN were evaluated, the number of partici-
pants evaluated in this study is relatively small. How-
ever, this number is still higher than in most cited
studies. Additionally, all participants underwent an im-
munosuppressive treatment protocol selected by the
center and not widely recruited, but this was undoubt-
edly efficient in severe cases of glomerulonephritis
[25–33]. Although these disadvantages may detract
from the results of post-treatment MIF evaluation, and
a retrospective analysis (R and NR subdivisions) may
be presumed to be less significant than a prospective
trial, the value of multivariable logistic evaluation
using MIF as an exclusive contributory predictor of
therapy outcomes should not be underestimated.
Conclusion
In conclusion, although urinary MIF excretion is highly
elevated in patients with primary GN, this serum con-
centration is not significantly higher than in healthy
participants.
The study did not confirm that MIF has any prognostic
value in the course of non-proliferative primary glomerulo-
nephritis. In contrast, in participants with proliferative GN,
a higher MIF urinary excretion value was a marker of
unfavorable therapy outcomes, whereas lower urinary MIF
in these patients may be linked with a good prognosis.
Additionally, in patients with proliferative GN who posi-
tively responded to therapy, the immunosuppressive treat-
ment significantly reduced urinary MIF. In Non-Responders
urinary MIF measurements may help to reconsider the
choice of the immunosuppressive regimen during the early
stage of the treatment and may add impetus to the search
for new therapeutic strategies.
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